491 related articles for article (PubMed ID: 28570924)
1. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
[TBL] [Abstract][Full Text] [Related]
3. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.
Hegde NC; Kumar A; Patil AN; Bhattacharjee S; Gamad N; Kasudhan KS; Kumar V; Rastogi A
Acta Diabetol; 2023 Oct; 60(10):1311-1331. PubMed ID: 37322184
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis.
Al-Hindi B; Mohammed MA; Mangantig E; Martini ND
J Am Pharm Assoc (2003); 2024; 64(1):9-26.e6. PubMed ID: 37844733
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Erondu N; Desai M; Ways K; Meininger G
Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064
[TBL] [Abstract][Full Text] [Related]
7. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
Li CX; Liu TT; Zhang Q; Xie Q; Geng XH; Man CX; Li JY; Mao XY; Qiao Y; Liu H
Front Pharmacol; 2023; 14():1275060. PubMed ID: 37905204
[No Abstract] [Full Text] [Related]
8. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
Zhou Y; Wang FR; Wen FF; Li C; Ye TT
Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
[TBL] [Abstract][Full Text] [Related]
9. Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database.
Abiru N; Nakatsuji Y; Noguchi M; Tsuboi K
Expert Opin Drug Saf; 2023; 22(8):697-706. PubMed ID: 36946980
[TBL] [Abstract][Full Text] [Related]
10. Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression.
Sridharan K; Sivaramakrishnan G
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541972
[No Abstract] [Full Text] [Related]
11. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Danne T; Garg S; Peters AL; Buse JB; Mathieu C; Pettus JH; Alexander CM; Battelino T; Ampudia-Blasco FJ; Bode BW; Cariou B; Close KL; Dandona P; Dutta S; Ferrannini E; Fourlanos S; Grunberger G; Heller SR; Henry RR; Kurian MJ; Kushner JA; Oron T; Parkin CG; Pieber TR; Rodbard HW; Schatz D; Skyler JS; Tamborlane WV; Yokote K; Phillip M
Diabetes Care; 2019 Jun; 42(6):1147-1154. PubMed ID: 30728224
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials.
Bhanushali KB; Asnani HK; Nair A; Ganatra S; Dani SS
Curr Probl Cardiol; 2024 May; 49(9):102664. PubMed ID: 38789017
[TBL] [Abstract][Full Text] [Related]
13. Treatment of a Severe Form of Euglycemic Ketoacidosis in a Patient Treated with SGLT-2 Inhibitors with the Aid of Somatostatin.
Torre A; Bisogno N; Botta C; Caiazza A; D'Angelo F; Del Giudice L; Fiorentini P; Marzano L; Nigro R; Sassone D; Torre P; Vicedomini D
G Ital Nefrol; 2023 Aug; 40(4):. PubMed ID: 37910214
[TBL] [Abstract][Full Text] [Related]
14. Fournier's gangrene and diabetic ketoacidosis with lower-than-anticipated glucose levels associated with SGLT-2 inhibitor: A double trouble.
Vadi S; Ismail A; Kapoor D
Med J Armed Forces India; 2023; 79(2):225-228. PubMed ID: 36969130
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations.
Maffei P; Bettini S; Busetto L; Dassie F
Diabetes Metab Syndr Obes; 2023; 16():3579-3598. PubMed ID: 37964939
[TBL] [Abstract][Full Text] [Related]
16. The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews.
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00145. PubMed ID: 32704566
[TBL] [Abstract][Full Text] [Related]
17. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review.
Morace C; Lorello G; Bellone F; Quartarone C; Ruggeri D; Giandalia A; Mandraffino G; Minutoli L; Squadrito G; Russo GT; Marini HR
Metabolites; 2024 May; 14(5):. PubMed ID: 38786741
[TBL] [Abstract][Full Text] [Related]
18. Inpatient case characteristics of SGLT2 inhibitor-associated diabetic ketoacidosis: a retrospective study.
Yang Z; Zhang W; Chen H; Peng Q
Eur J Hosp Pharm; 2024 Jun; ():. PubMed ID: 38844329
[TBL] [Abstract][Full Text] [Related]
19. Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy.
Westcott GP; Segal AR; Mitri J; Brown FM
Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00117. PubMed ID: 32318635
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of dexamethasone on diabetic ketoacidosis complicated with acute pancreatitis: A randomized controlled study.
Zhang J; He J
Medicine (Baltimore); 2023 Oct; 102(41):e35320. PubMed ID: 37832092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
